touchIMMUNOLOGY had the pleasure of discussing with Dr Ana-Maria Orbai (Johns Hopkins University School of Medicine, Baltimore, MD, USA) the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) instrument and its use in assessing the effect of guselkumab on general health outcomes in patients with psoriatic arthritis in the DISCOVER-1 trial (NCT03162796).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial’ (Abstract number: 1332) was presented at the ACR Convergence, 5-9 November.
Questions
- Could you give us an overview of the symptoms that negatively impact health-related quality of life in psoriatic arthritis (PsA)? (0:19)
- Why was it important to validate the PROMIS-29 profile in patients with active psoriatic arthritis? (0:52)
- What did the DISCOVER-1 analysis teach us about the impact of guselkumab on joint and skin clinical manifestations of PsA? (1:55)
- Could you tell us a little about the objectives and findings from this current analysis? (2:50)
- What will be the likely role of guselkumab in the treatment paradigm for PsA? (4:22)
Disclosures: Dr Ana-Orbai has acted as a consultant for Eli Lilly, Novartis, Janssen, Pfizer and UCB, and received grant/ research support from AbbVie, Eli Lilly, Celgene, Janssen and Horizon.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
